To confirm that the genetic deletion of OPN inhibits debris-stimulated tumor growth and to establish the clinical relevance of pharmacologic OPN modulation, we used an OPN-neutralizing Ab in the CT26 debris-stimulated tumor model. The gene discussed is DDX53; the disease is neoplasm.